Print  |  Close

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)


Active: Yes
Cancer Type: Gynecologic Cancers
Ovarian Cancer
Primary Peritoneal Cancer
Unknown Primary
NCT ID: NCT07318558
Trial Phases: Phase III Protocol IDs: 2870-021 (primary)
NCI-2026-02084
2023
2023-508047-40-00
ENGOT-ov85
GOG-3102
jRCT2031250647
MK-2870-021
U1111-1297-5158
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Merck Sharp and Dohme LLC
NCI Full Details: http://clinicaltrials.gov/show/NCT07318558

Summary

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for
OC may start with surgery to remove as much of the cancer as possible. After surgery,
people may receive chemotherapy. After chemotherapy, standard care options may include:

- Maintenance treatment, which is used after another therapy to keep the cancer from
growing, spreading, or coming back. Bevacizumab is a targeted therapy used as
standard maintenance treatment. Targeted therapy works to control how specific types
of cancer cells grow and spread.

- Observation, which is watching to see if cancer grows or worsens

The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy.
The goal of this study is to learn if people who receive sac-TMT maintenance treatment
with or without bevacizumab live longer without the cancer getting worse than people who
receive standard care.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.